Positive outcomes of denosumab in the treatment of central giant cell lesions: case series

We report three cases of CGCL managed with denosumab. Two of the patients were female adults presenting symptomatic lesions in maxilla. They received 120 mg subcutaneous denosumab monthly for 6 and 12 months (2 extra doses in the first month). The other was a 16-year-old male patient with Noonan syndrome, previously treated with calcitonin, who had mandibular and maxillary lesions.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Source Type: research